As of January 23, 2025, MiNK Therapeutics (INKT) has a market cap of $40.027 million USD. According to our data, MiNK Therapeutics is ranked No.8282 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $40.03 M |
44.91%
|
Dec 31, 2024 | $27.62 M |
-34.86%
|
Dec 29, 2023 | $42.40 M |
-59.00%
|
Dec 30, 2022 | $0.10 B |
-41.48%
|
Dec 31, 2021 | $0.18 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Market Cap | = | INKT Stock Price | * | INKT Shares Outstanding |
= | $1.01 | * | 39.63 M | |
= | $40.03 M |